IL18 and myeloid sarcoma: Our data confirm the involvement of pro-inflammatory mediators, such as TNF-α, IL-1β, IL-18, and HMGB-1, matured by NALP3 inflammasome, but also IL-18BP, IL-12/23, in the pathophysiology and clinical course of MS (48).